Literature DB >> 19401539

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

David M Pollock1, Erika I Boesen, Stephen M Black.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19401539      PMCID： PMC2800997          DOI： 10.1124/mi.9.2.6

Source DB:  PubMed          Journal:  Mol Interv        ISSN： 1534-0384


× No keyword cloud information.
  33 in total

1.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

Authors:  C Rubens; R Ewert; M Halank; R Wensel; H D Orzechowski; H P Schultheiss; G Hoeffken
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

2.  Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.

Authors:  J F Jasmin; M Lucas; P Cernacek; J Dupuis
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

3.  [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a neuropeptide antagonist, blocks binding, Ca2(+)-mobilizing, and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells.

Authors:  I Fabregat; E Rozengurt
Journal:  J Cell Physiol       Date:  1990-10       Impact factor: 6.384

4.  Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy.

Authors:  B Rolinski; A Heigermoser; E Lederer; J R Bogner; O Loch; F D Goebel
Journal:  Infection       Date:  1999       Impact factor: 3.553

5.  Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins.

Authors:  T F Lüscher; Z Yang; M Tschudi; L von Segesser; P Stulz; C Boulanger; R Siebenmann; M Turina; F R Bühler
Journal:  Circ Res       Date:  1990-04       Impact factor: 17.367

6.  Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.

Authors:  Masahiro Nishida; Keiko Eshiro; Yuka Okada; Masanori Takaoka; Yasuo Matsumura
Journal:  J Cardiovasc Pharmacol       Date:  2004-08       Impact factor: 3.105

7.  Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow.

Authors:  Stephen M Black; Eugenia Mata-Greenwood; Robert W Dettman; Boaz Ovadia; Robert K Fitzgerald; Olaf Reinhartz; Stefan Thelitz; Robin H Steinhorn; Rene Gerrets; Karen Hendricks-Munoz; Gregory A Ross; Janine M Bekker; Michael J Johengen; Jeffrey R Fineman
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

8.  Sitaxsentan therapy for pulmonary arterial hypertension.

Authors:  Robyn J Barst; David Langleben; Adaani Frost; Evelyn M Horn; Ronald Oudiz; Shelley Shapiro; Vallerie McLaughlin; Nicholas Hill; Victor F Tapson; Ivan M Robbins; Diane Zwicke; Benjamin Duncan; Richard A F Dixon; Lyn R Frumkin
Journal:  Am J Respir Crit Care Med       Date:  2003-11-20       Impact factor: 21.405

Review 9.  Bosentan: a dual endothelin receptor antagonist.

Authors:  Lewis J Rubin; Sébastien Roux
Journal:  Expert Opin Investig Drugs       Date:  2002-07       Impact factor: 6.206

Review 10.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Alessandra Manes; Luca Negro; Massimiliano Palazzini; Maria Letizia Bacchi-Reggiani; Angelo Branzi
Journal:  Eur Heart J       Date:  2009-01-20       Impact factor: 29.983
View more
  1 in total

1.  Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Authors:  Shiao-Pei Weathers; Julie Rood-Breithaupt; John de Groot; Gail Thomas; Marianna Manfrini; Marta Penas-Prado; Vinay K Puduvalli; Christian Zwingelstein; W K Alfred Yung
Journal:  Neurooncol Adv       Date:  2021-10-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.